Strongbridge Biopharma plc (NASDAQ:SBBP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “

Separately, HC Wainwright increased their target price on shares of Strongbridge Biopharma plc from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, January 25th.

Strongbridge Biopharma plc (NASDAQ:SBBP) opened at 4.60 on Wednesday. The stock’s market capitalization is $162.54 million. The company’s 50-day moving average is $4.35 and its 200 day moving average is $3.56. Strongbridge Biopharma plc has a 1-year low of $2.00 and a 1-year high of $6.24.

Strongbridge Biopharma plc (NASDAQ:SBBP) last issued its earnings results on Tuesday, May 16th. The biotechnology company reported ($0.33) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.16. Equities analysts predict that Strongbridge Biopharma plc will post ($2.11) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/05/19/strongbridge-biopharma-plc-sbbp-stock-rating-lowered-by-zacks-investment-research.html.

Several large investors have recently modified their holdings of SBBP. Boxer Capital LLC acquired a new stake in shares of Strongbridge Biopharma plc during the fourth quarter worth approximately $2,256,000. Opaleye Management Inc. acquired a new stake in shares of Strongbridge Biopharma plc during the fourth quarter worth approximately $2,784,000. Broadfin Capital LLC boosted its stake in shares of Strongbridge Biopharma plc by 74.7% in the fourth quarter. Broadfin Capital LLC now owns 2,894,581 shares of the biotechnology company’s stock worth $6,947,000 after buying an additional 1,237,875 shares during the period. Finally, Vivo Capital LLC acquired a new stake in shares of Strongbridge Biopharma plc during the fourth quarter worth approximately $7,200,000. Institutional investors and hedge funds own 42.86% of the company’s stock.

Strongbridge Biopharma plc Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

5 Day Chart for NASDAQ:SBBP

Receive News & Stock Ratings for Strongbridge Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma plc and related stocks with our FREE daily email newsletter.